Boehringer Ingelheim and CureVac have entered an exclusive global pharma licensing deal and development partnership to focus on CureVac’s CV9202, netting CureVac $556 million ($45 million upfront).
CureVac will receive milestone payments and royalties on sales.
CV9202 is an investigational therapeutic mRNA vaccine in early clinical development for the treatment of lung cancer.
This collaboration fits into Boehringer Ingelheim’s mission to focus on cancer therapies through novel treatment options with high therapeutic value.
Boehringer Ingelheim will start investigating CV9202 in two different lung cancer settings: in combination with afatinib in patients with advanced or metastatic epidermal growth factor receptor mutated non-small cell lung cancer, and in combination with chemo-radiation therapy in patients with unresectable stage III NSCLC.
CV9202 is a combination of mRNA molecules coding for six antigens overexpressed in lung cancer, designed to spawn an immune system response against the tumor.
In initial clinical trials, CV9202 showed that it could generate immune responses against all anti-tumor antigens.
For further deal information visit Current Agreements (subscription required)
Report: Partnering Deals and Alliances with Boehringer Ingelheim
View: Partnering Scorecard in CP Insight– view top life science partnering deals by value
View: DealMetrics in CP Insight – the latest deal trend infographics for life science deal making
View: CP Insight’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: CP Insight’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity